FDA grants priority review to Merck Ebola vaccine

The organization granted Breakthrough Therapy Designation to V920 in July 2016 and it now has a target action date of March 14, 2020
Source: PharmaManufacturing.com - Category: Pharmaceuticals Source Type: news